NuVision Biotherapies attend Medica: International Trade Fair to develop new distribution channels

NuVision Biotherapies is joining the Department of International Trade (DIT) at Medica World Trade Fair this November to expand their international profile

Medica is the world’s largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics, and pharmaceuticals. Medica is a world forum for medicine and this year will take place in Düsseldorf, Germany between the 15th – 18th of November. NuVision (https://www.nu-vision.co.uk) will be joining the Department of International Trade (https://www.gov.uk/government/organisations/department-for-international-trade) with the objective of expanding our international presence through fostering new key commercial partnerships. Our mission is to provide effective human tissue-based therapy solutions across multiple clinical specialities, including ophthalmology, diabetic ulcers, and wider wound care.

NuVision Biotherapies platform technology is Tereo® processed amniotic membrane.  The proprietary and patented Tereo process uniquely preserves the natural qualities and healing properties of fresh amniotic membrane in a dry and room temperature stable product. Stored on the shelf, NuVision’s products can be easily accessed at the point of care, delivering improved clinical utility and enhanced benefits. The company’s disruptive Ophthalmology product, Omnigen®, is already transforming the way eye disease is managed surgically.

Secondary to this, NuVision have also developed OmniLenz®, a bandage contact lens specially designed and developed with Menicon Ltd (https://www.menicon.co.uk) to effectively apply and retain Omnigen, Tereo processed amniotic membrane to the ocular surface. OmniLenz application of Omnigen is a simple 4-6 minute procedureeliminating the need for sutures or surgery,  This uniquely allows transplantation of amniotic membrane e in an outpatient setting. In clinic application of Omnigen is transforming the management of an ocular surface disease. A recent study, 86% of patients suffering refractory persistent epithelial defects had complete or partial healing in 25 days, with an average of 1.2 applications of Omnigen.

Amniotic membrane
Figure 1. The amniotic sac, which holds the foetus during pregnancy with the amniotic membrane outlined with the blue and green coloured line.

“Medica offers the opportunity for NuVision to connect with potential international commercial partners and broaden our international network to allow better access to Tereo processed amniotic membrane treatment across the globe.” said Andrew Hopkinson, Founder and Chief Scientific Officer of NuVision. “This presents a truly exciting time for NuVision as we expand the accessibility and availability of Omnigen and OmniLenz products to provide international patients with the best potential care”. 

NuVision will be joining the UK’s Department for International Trade Stand during the conference and would like to thank the DIT for their support and allowing NuVision to work alongside them. To book an appointment to meet a NuVision Biotherapies representative at Medica 2021 or would like to speak to NuVision regarding the potential of becoming a distributor, please email support@nu-vision.co.uk or visit: https://www.nu-vision.co.uk/distributors/

NuVision Biotherapies 

Based in MediCity, Nottingham, NuVision Biotherapies is a regenerative medicine company spun out from the University of Nottingham. NuVision was established in 2015, founded on investment from Mercia Fund Management, to develop and bring to market cutting edge, regenerative therapies.

About Omnigen

Omnigen Tereo processed amniotic membrane, is a patented dry preparation of human amniotic membrane.  Amniotic membrane is the innermost layer of the placental sac, which protects and holds the foetus during pregnancy.  NuVision upcycles and transforms this waste product of birth into an effective wound care product. The Tereo manufacturing process, developed at the University of Nottingham’s Academic Ophthalmology department, transforms this waste product of birth into a sterile and stable dry regenerative therapy that can be easily shipped and accessed anywhere in the world. Omnigen is applied directly to the wound dry and is rapidly and effectively rehydrated using surrounding moisture to immediately reactivate the beneficial properties to promote tissue repair and healing in a variety of ways. The product represents a unique and versatile “off-the-shelf” regenerative product, and it may be stored long-term. The Tereo process preserves the wound healing action and provides surgeons with an effective sight saving therapy that could provide a meaningful benefit to patients, including those suffering from ocular surface disease and conditions with unmet medical need.

About OmniLenz 

OmniLenz is a bespoke BCL designed to apply and hold Omnigen at the ocular surface without the need for sutures or surgery. OmniLenz is manufactured exclusively for NuVision by Menicon, UK. Omnigen can be applied by OmniLenz using a simple 4 – 6-minute procedure in an outpatient setting. The decision to apply Omnigen to the ocular surface using OmniLenz is at the discretion of the clinician.

Continue reading:

www.nu-vision.co.uk